Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI once daily versus fluticasone propionate twice daily in Asian adolescents and adults with persistent asthma
2015-004868-11Phase 3
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluticasone, vilanterol and fluticasone propionate in asthma and persistent asthma (2 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in daily evening peak expiratory flow averaged over the 12-week treatment period.
02
Drugs
fluticasonevilanterolfluticasone propionate
03
Conditions
asthmapersistent asthma
Beyond the preview
Go deeper on 2015-004868-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004868-11.